Accéder au contenu
Merck

Secretion, blood levels and cutaneous expression of TL1A in psoriasis patients.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica (2015-04-25)
Anders Elm Pedersen, Esben Gjerløff Wedebye Schmidt, Jesper Freddie Sørensen, Carsten Faber, Boye Schnack Nielsen, Kim Holmstrøm, Silje Haukali Omland, Peter Tougaard, Søren Skov, Bo Bang
RÉSUMÉ

TL1A is a TNF-like cytokine which has been shown to co-stimulate TH1 and TH17 responses during chronic inflammation. The expression of this novel cytokine has been investigated in inflammatory disorders like rheumatoid arthritis and inflammatory bowel disease, but little is known about expression and induction in psoriasis. Indeed, the pathogenesis in psoriasis is still not fully understood and it is speculated that cytokines other than TNF-α are important in subsets of patients. Also, for patients with severe disease that are treated with systemic anti-TNF-α blockade, novel candidates to be used as disease and response biomarkers are of high interest. Here, we demonstrate TL1A expression in biopsies from psoriatic lesions. Also, we investigated spontaneous and induced TL1A secretion from PBMCs and blood levels from a cohort of psoriasis patients. Here, increased spontaneous secretion from PBMCs was observed as compared to healthy controls and a small subset of patients had highly elevated TL1A in the blood. Interestingly, activation of PBMCs with various cytokines showed a decreased sensitivity for TL1A activation in psoriasis patients compared to healthy controls.TL1A levels in blood and biopsies could not be correlated with disease activity with this patient cohort. Thus, additional large-scale studies are warranted to investigate TL1A as a biomarker.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
3-Amino-9-ethylcarbazole, ≥95% (HPLC), powder
Sigma-Aldrich
3-Amino-9-ethylcarbazole, tablet
Sigma-Aldrich
Interleukin-18 from rat, >97% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder